Do you want to read an article? Please log in or register.
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study
Further Publications
Related content
Gastritis
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial
Lancet Gastroenterol Hepatol
Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hébuterne X, Arnesson K, Knittel T, Kowalski J, Neurath MF, Sandborn WJ, Reinisch W, CONDUCT study group.
doi: 10.1016/S2468-1253(20)30301-0
Inflammatory Bowel Disease
Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate to Severe Ulcerative Colitis
Gastroenterology.
Sandborn WJ, Cyrille M, Hansen MB, Feagan BG, Loftus EV Jr, Rogler G, Vermeire S, Cruz ML, Yang J, Boedigheimer MJ, Abuqayyas L, Evangelista CM, Sullivan BA,
Reinisch W
doi: 10.1053/j.gastro.2018.11.035.
COMMENTED
Inflammatory Bowel Disease
Long-Term Efficacy And Safety Of Ozanimod In Moderate-To-Severe Ulcerative Colitis: Results From The Open-Label Extension Of The Randomized, Phase 2 Touchstone Study
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
J Crohns Colitis
Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G
doi: 10.1093/ecco-jcc/jjab012
Inflammatory Bowel Disease
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
N Engl J Med.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S, VARSITY Study Group.
doi: 10.1056/NEJMoa1905725.
Further Publications
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial
Lancet Gastroenterol Hepatol
Hanauer S, Liedert B, Balser S, Brockstedt E, Moschetti V, Schreiber S
doi: 10.1016/S2468-1253(21)00252-1
Inflammatory Bowel Disease
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Lancet
Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L
doi: 10.1016/S0140-6736(21)00666-8
Inflammatory Bowel Disease
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
Gastroenterology.
Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, Tuttle JL, Klekotka P, Friedrich S, Durante M, Morgan-Cox M, Laskowski J, Schmitz J, D'Haens GR
doi: 10.1053/j.gastro.2019.08.043.
Inflammatory Bowel Disease
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis
Gastroenterology.
Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J
doi: 10.1053/j.gastro.2019.10.035.
ColonoscopyGastrointestinal CancerInflammatory Bowel Disease
Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Gastroenterol Hepatol.
Taha AS, McCloskey C, McSkimming P, McConnachie A
doi: 10.1016/